Verapamil sustained release - Beijing CoSci Med Tech

Drug Profile

Verapamil sustained release - Beijing CoSci Med Tech

Latest Information Update: 27 Jul 2016

Price : $50

At a glance

  • Originator Beijing CoSci Med-Tech
  • Class Antihypertensives; Antimigraines; Class IV antiarrhythmics; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules; Vasodilators
  • Mechanism of Action Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Essential hypertension

Most Recent Events

  • 27 Jul 2016 Chemical structure information added
  • 22 Jul 2016 Investigation in Essential hypertension in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top